Clinical Research Trials

AML 58: Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy. PI: Suman Kambhampati, MD

Facility: Research Medical Center

AML 64: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. PI: Suman Kambhampati, MD

Facility: Research Medical Center

CLL 51: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322). PI: Suman Kambhampati, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 136: A Phase 3, two-stage, randomized, multicenter, open label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) vs Daratumumab, Bortezomib and Dexamethasone (DVD) in subjects with relapsed or refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM). PI: Suman Kambhampati, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM-001: A Phase 1/2a Study of Modakafusp alfa in combination with Daratumumab Subcutaneous (SC) (Moda + Dara) in patients with relapsed or refractory Multiple Myeloma. PI: Suman Kambhampati, MD

Facility: Research Medical Center

MM-002: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). PI: Suman Kambhampati, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

KC-BRE-002: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib. PI: Aruna Rokkam, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Catalyst:

Evaluates the safety and effectiveness of the Amulet LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. Principal Investigator: Dr. James Marcum

Facility: Overland Park Regional Medical Center, Research Medical Center

Champion AF:

To determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

Define AF:

Aims to improve the understanding of how data from the Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM) can be used to guide the management of Afib. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center, Menorah Medical Center

Leadless II:

Designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a single chamber pacemaker. Principle Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center

LUX-Dx PERFORM:/p>

To characterize the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device. The study will also collect data to characterize the performance of arrhythmia detection. Finally, data collected will be used to analyze and characterize the ICM system-related safety events. Principal Investigator: Dr. Scott Koerber

Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center

RELIEVE-HF:

To provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System to improve clinical outcomes in a certain high-risk subset of symptomatic patients suffering from HF. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

Solve CRT:

To study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. Principal Investigator: Dr. Dhanunjaya Lakkireddy

Facility: Overland Park Regional Medical Center, Research Medical Center

KC-GI-001: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT). PI: Mohammad Mozayen, MB

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-001: A Phase 2 Open label, Multicenter study to evaluate efficacy and safety of ZN-C3 in adult women with recurrent or persistent uterine serous carcinoma. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-003: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-004: A Phase 3, Randomized, Placebo-Controlled, Double-Blind multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 Wild-Ty[e, advanced or recurrent endometrial carcinoma. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN-005: A Phase 1B22 Baseky study of ACR-368 as monotherapy and in combiinatio with Gemcitabien in Adults with platinum-resistant ovarian carcinoma, Endometrial Adenocarcinoma and Urothelial carcinoma based on Acrivon Oncosignature status. PI: K. Shawn Lybarger, DO

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

KC-CNS-001: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma. PI: Amandeep Kalra, MD

Facility: Research Medical Center

KC-CNS-002: A Parallel-group, Two-staged, Phase 2/3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with progressive NF2 mutated Meningiomas. PI: Amandeep Kalra, MD

Facility: Research Medical Center

There are currently no research trials.

KC-LUN-004: A Radomized, double-blind international multicenter Phase III study to evaluate the anti-tumor efficacy and safte of HLX10 or placebo in combo with chemo (carbo/sisplatin Etoposide) and concurrent radiotherapy in patients with Limited-stage (3 or less) Small Cell Lung Cancer (LS-SCLC). PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN-002: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies. PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN-003: A Randomized, open-label study of HLX10 plus chemo (carbo-Etoposide) in comparison with Atezolizumab pl use chemo in Previously untreated US patient with extensive Stage (4) Small Cell Lung Cancer (ES-SCLC). PI: Joseph Stilwill, MD

Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center